Zacks: Analysts Set $23.33 Price Target for Catabasis Pharmaceuticls Inc. (CATB)
Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) has been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price objective of $23.33 for the company and are forecasting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also given Catabasis Pharmaceuticls an industry rank of 105 out of 265 based on the ratings given to related companies.
CATB has been the subject of several research analyst reports. Zacks Investment Research raised Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research report on Tuesday, July 5th. Wedbush reissued an “outperform” rating and set a $17.00 price objective on shares of Catabasis Pharmaceuticls in a research report on Thursday, October 13th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/zacks-analysts-set-23-33-price-target-for-catabasis-pharmaceuticls-inc-catb.html
Catabasis Pharmaceuticls (NASDAQ:CATB) traded down 1.1339% during midday trading on Wednesday, reaching $4.7258. The company’s stock had a trading volume of 56,829 shares. Catabasis Pharmaceuticls has a 52 week low of $3.31 and a 52 week high of $10.83. The stock has a 50 day moving average of $4.76 and a 200 day moving average of $4.74. The firm’s market capitalization is $72.69 million.
Catabasis Pharmaceuticls (NASDAQ:CATB) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.04. On average, equities research analysts predict that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. purchased a new stake in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned 0.18% of Catabasis Pharmaceuticls as of its most recent SEC filing. 57.27% of the stock is owned by hedge funds and other institutional investors.
Catabasis Pharmaceuticls Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.